Stock Price Forecast

April 27, 2021


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Seneca Biopharma Inc chart...

About the Company

Neuralstem Inc. is a biotechnology company headquartered in Rockville, Maryland that specializes in developing commercial-scale production of multiple types of central nervous system stem cells. In October 2019 Neuralstem announces that the company has changed its name to Seneca Biopharma, Inc. In April 2021 Seneca Biopharma merged with Leading BioSciences to form the combined company Palisade Bio, Inc.

CEO

I. Richard Garr

Exchange

NASDAQ CAPITAL MARKET

Website

https://senecabio.com/

$0M

Total Revenue

5

Employees

$20M

Market Capitalization

-1.42

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SNCA News

ABVC BioPharma Inc ABVC

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

First Wave BioPharma, Inc.

2y ago, source: CNN

First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases.

Sunshine Biopharma, Inc. (SBFM)

1mon ago, source: Yahoo Finance

NEW YORK, NY / ACCESSWIRE / February 15, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of ...

Immix Biopharma Suspends Stock Offering Pending New Prospectus

1mon ago, source: Hosted on MSN

Immix Biopharma, Inc. (IMMX) has released an update. Immix Biopharma, Inc. has halted the offering of its common stock shares under a previously dated prospectus supplement, in connection with a ...

Aytu BioPharma Inc AYTU

5d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Theravance Biopharma Inc.

1mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

ABIO ARCA biopharma, Inc.

4d ago, source: Seeking Alpha

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is ...

Matinas BioPharma Holdings, Inc.

2mon ago, source: CNN

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery ...

Kinnate Biopharma sells rights of exarafenib to Pierre Fabre laboratories

17d ago, source: Hosted on MSN

Kinnate Biopharma Inc (NASDAQ:KNTE) has entered into an asset purchase agreement with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. The sale of global ...

AVBP ArriVent BioPharma, Inc.

3d ago, source: Seeking Alpha

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of ...

Aytu BioPharma, Inc. (AYTU) Interactive Stock Chart - Yahoo Finance

3y ago, source: Yahoo Finance

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call Transcript February 14, 2024 Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.25.

Aytu BioPharma Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...